Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations, and compounds that provide therapies for chronic inflammatory disease and neurologic disorders. Rock Creek’s lead compound, Anatabine Citrate, is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of multiple sclerosis, Alzheimer’s disease, and auto-immune thyroiditis. For more information, visit the company’s website at www.rockcreekpharmaceuticals.com